Synopsis:-Citing smartphone volume pressure from rising memory chip prices and uncertainty around the Vivo joint venture approval, global brokerage UBS has cut its price target on Dixon Technologies by 33% to Rs.13,800 while maintaining its ‘Buy’ rating, arguing that near-term risks are now largely priced into the stock.
Shares of India’s largest EMS company are back in the spotlight, as brokerage re-rates with two familiar headwinds refusing to fade: surging global memory chip prices and a joint venture approval that remains stuck in regulatory limbo.
With a market capitalization of Rs. 67,957 crore, the shares of Dixon Technologies (India) Ltd. were trading at Rs. 11,166 per share, with a 52-week range of Rs. 18,471 to Rs. 9,600. The stock trades at a trailing P/E of 48.2x.
What UBS Said and Why
UBS has maintained a ‘Buy’ rating on Dixon Technologies but reduced its price target to Rs.13,800 from Rs.20,600 earlier, still expecting an upside of upto 24 percent. The brokerage’s core argument is that while near-term conditions are difficult, the market has already absorbed much of that bad news into the stock price.
UBS expects higher smartphone prices to weigh on organic volume growth in FY27, with a recovery likely in FY28. Margins may also come under pressure in FY27 due to ongoing backward integration, with benefits expected to accrue from FY28 onwards. Key risks flagged by UBS include potential delays in PN3 approvals for the Vivo joint venture, which could account for nearly 20 percent of FY28 earnings, as well as any worsening of the global memory chip shortage.
The Memory Price Problem
The near-term volume concern is not specific to Dixon alone. Memory prices have surged over 100 percent since December 2025 and remained elevated through March 2026, prompting smartphone companies to raise prices across models and new launches. Major brands such as Samsung, Oppo, Xiaomi, Realme, Nothing, and Vivo have increased prices by up to 40 percent for select models, with an average hike of around Rs.1,500. For Dixon, which counts several of these brands as manufacturing clients, softer consumer demand from price-sensitive segments translates directly into lower assembly volumes.
Broader Analyst View
UBS is not alone in its cautious-but-constructive stance. According to Bloomberg data, 22 out of 32 analysts covering the stock have a ‘Buy’ rating, four recommend ‘Hold,’ and six have a ‘Sell’ rating. Motilal Oswal has also reiterated ‘Buy’ with a target of Rs.14,700, while HSBC maintains a ‘Hold’ with a Rs.11,500 target, citing delayed Vivo JV approval and FY27 volume impact.
For Q3 FY26, the company reported consolidated operating revenues of Rs.10,672 crore compared to Rs.10,454 crore in the same period last year, with operating EBITDA rising to Rs.414 crore from Rs.391 crore year-on-year. Net profit for the quarter came in at Rs.321 crore, up 48 percent year-over-year.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post EMS Stock That Manufactures Vivo’s Smartphones to Buy Now for an Upside of 24%; Do You Own It? appeared first on Trade Brains.